Table 3 Summary of clinical trials with NGF on skin ulcers
From: Nerve growth factor: from the early discoveries to the potential clinical use
Disease | Study type | NGF type and dosage | Delivery route | Outcome | Side effects | References |
|---|---|---|---|---|---|---|
Diabetic foot ulcers | Three patients case report. | Mouse NGF. 25 μg/day for 4 weeks. | Topical (skin). | Progressive restoration of nerve function and relapse of ulcers within 5–14 weeks since the beginning of treatment. | Not reported. | [154] |
Vasculitic ulcers | Eight patients case report. | Mouse NGF. 50 μg/day for 4 weeks. | Topical (skin). | Ulcers healing within 8 weeks in rheumatoid arthritis patients (n=4). Failure of ulcers healing in systemic sclerosis patients (n=4). | Not reported. | [155] |
Pressure ulcers | Single patient case study. | Mouse NGF. | Topical (skin). | Ulcer size reduced by 1/3 after 15 days treatment. | Not reported. | [156] |
|  | Randomized, double-blind, placebo-controlled trial. | Mouse NGF. | Topical (skin). | Reduction of ulcer area in the 6 weeks follow-up. | Not reported. | [157] |
Lower limb crush syndrome | Single patient case study. | Mouse NGF. 10 μg every eight hours for seven days. | Subcutaneous. | Reduction of overall ischemic area. Reduction of the area undergoing calcaneal escharotomy. | Not reported. | [158] |